Omnicell, Inc.
As of Oct 22, 2026, Omnicell is in Stage 4, the downtrend phase, now in week 10 (since Aug 17, 2026). It closed at $37.10, 27.8% below its 52-week high and below its 200-day average, which is falling.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is OMCL early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
OMCL among Health Information Services8th of 41 by relative strength
All 41 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | AMWL | Stage 2 · wk 25 | 97 | +7.4% |
| 2 | HNGE | Stage 2 · wk 20 | 96 | +19.1% |
| 3 | BTSG | Stage 3 · wk 8 | 94 | +9.1% |
| 4 | NRC | Stage 3 · wk 4 | 93 | −0.1% |
| 5 | SOPH | Stage 2 · wk 24 | 91 | −12.7% |
| 6 | HTFL | Stage 2 · wk 10 | 87 | +17.0% |
| 7 | HSTM | Stage 2 · wk 17 | 77 | +20.3% |
| 8 | OMCL | Stage 4 · wk 10 | 70 | +12.5% |
Omnicell: quick answers
What stage is Omnicell in?
As of Oct 22, 2026, Omnicell (OMCL) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 17, 2026 and is in week 10. What the four stages mean
Is Omnicell in an uptrend?
No. Omnicell is in a Stage 4 downtrend. It trades 5.9% below its 200-day average, which is falling.
How far is Omnicell from its 52-week high?
Omnicell closed at $37.10 on Oct 22, 2026, 27.8% below its 52-week high of $51.39. Its 52-week low is $29.57.
How has Omnicell performed over the past year?
As of Oct 22, 2026, Omnicell is up 19.8% over the past year and down 17.8% so far in 2026.
Which sector and industry is Omnicell in?
Omnicell is in the Health Information Services industry, part of the Health Care sector.
About this companyHealth Care· Health Information Services
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.